VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy

CompletedOBSERVATIONAL
Enrollment

462

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

June 30, 2023

Study Completion Date

January 31, 2024

Conditions
HCCRecurrence
Interventions
DRUG

PD-1 monoclonal antibody and lenvatinib

"Adjuvant PD-1 group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200mg IV over 21 days for 9 cycles.~Adjuvant PD-1 plus Lenvatinib group: Patient receives first adjuvant PD-1 monoclonal antibody 2-4 weeks postoperatively, 200 mg IV 21 days for 9 cycles; lenvatinib is initiated orally 2-4 weeks postoperatively for 6 months."

Trial Locations (1)

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER

NCT06253364 - VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy | Biotech Hunter | Biotech Hunter